· METHODS: Human primary Tenon's capsule fibroblastswerecultured ,treatedwithuptitrating concentrationsofolmesartan.Therateofinhibitionwas testedwithmethylthiazoltetrazolium (MTT)method. Real-timePCRwasperformedtoanalyzechangesin mRNAexpressionsofthefibrosis-relatedfactors:matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinase (TIMP-1,2) and proliferating cell nuclearantigen(PCNA).Thirtyrabbitsweredividedinto 5groups (3,7,14,21,and28d 
INTRODUCTION
G laucomafiltrationsurgery(GFS,trabeculectomy)isa classicoperationtotreatglaucoma.Thesurgeryitself can damagethe structuresoftheconjunctivaand subconjunctival tissue,whichstimulatesfibroblasts,as mediatedbymacrophages,neutrophilsandinflammatory cytokines(such astransforminggrowthfactor-beta, insulin-likegrowthfactor-1,IL-6) [1] [2] .Thesemoleculesare involvedincomplex processes,leadingtofurther extracellularmatrix(ECM)secretionandremodeling.Any overwhelmingactivitywithin thisprocesscancause overstimulationoffibroblasts,formationandaccumulationof extraneous ECM.Withthe participationof matrix metalloproteinases (MMPs)inECMremodelingandthe subsequentmatrixcontraction,scarringresults [3] . MMPsareasuperfamilyofzinc-dependentproteases,which hasmorethan20members,actedthroughcleavingand degradingtheECM.Activatedfibroblastsandmacrophages cansecreteMMPsduringtissuerepair.Tumorcellscanalso inducethesecretionofMMPstofacilitatetumorcell migrationandnewbloodvesselsformationtosupporttumor growth.TheactivityofMMPscanberegulatedandbalanced bytheendogenousinhibitortissueinhibitorofmatrix metalloproteinases(TIMPs) [4] [5] . StatuspostGFS,somepatientsexperienceexcessivetissue repairoftheTenon'scapsule.Theunrestrainedproliferation offibroblastsinducesastronginflammatoryreactionwith abundantECM(includingcollagenfibers)formation. Meanwhile,MMPsandTIMPsarestimulated:MMPs promotethecontractionoftheECM,whichresultsin fibrosisandscarringsurroundingthesurgicalcanalcreated foraqueoushumordrainage.Consequently,theintraocular pressurereboundsandindicatesthefailureoftheGFS. Therefore,manytopicalmedicationshavebeenstudiedto reducethefibrosisandscarringaftersurgerysothatthe filtrationblebsurvives.MMCand5-FUhavebeenapplied clinicallyforthispurpose [6] .Althoughthesedrugsmay 窑BasicResearch窑 Anti-proliferativeeffectofolmesartanonTenon's capsulefibroblasts achievethedesiredinhibitionoffibrosis,someobvious complicationsoccurwhenthesemedicationsareapplied,such asblebleakage,infectiousblebitis,lowintraocularpressure associatedwithmaculopathyandevenendophthalmitis [7] [8] . Olmesartan,apotentangiotensinIIreceptorblocker(ARB), isusedincardiovascularmedicineforthetreatmentof hypertension.AngiotensinII,inadditiontoitspotent vasoconstrictiveeffect,acts itstype1(AT1)receptorto promotethegenerationofreactiveoxygenspecies(ROS), vascularinflammation,fibrosis,andcellproliferation [9] [10] [11] [12] . TheemergingroleofangiotensinIIasapro-inflammatory factorhasbeenstudiedincardiology,pulmonology, dermatology,hepatology,andnephrology [13] [14] [15] .Thiseffect maybemediatedby thestimulationofreceptor AT1-activatedsecondmessengers,suchasdiacylglycerol and1-4-5-inositoltriphosphate,aswellastheactivationofC protein [16] .AngiotensinIIcanalsoactivatetheRas/p38 MAPK/CREBpathwayandERK1/2byregulating TGF-茁1/Smadsignalingincardiacfibroblasts,enhancingthe releaseofMMP-2byendothelialcells the pro-inflammatoryfactor,tumornecrosisfactor(TNF)-琢 (asa mechanismof vasoconstrictionandinflammation) [17] [18] . AntagonistsoftheangiotensinIItype1receptorinhibitthis pro-inflammatoryandfibroticeffect.Olmesartaneffectively prevents nonalcoholicsteatohepatitisandliverfibrosis, pulmonaryfibrosis,andscarringandremoldingoftheheart [19] [20] [21] . Dosimilareffectsofangiotensinanditsantagonistexistin theeyes?ThepresenceofangiotensinIIanditsreceptorshas beenconfirmedintheocularsystem,andtheirdistribution demonstratedtheexistenceofalocalrenin-angiotensin system(RAS)insteadofjustdiffusionfromthesystem [22] [23] . Thecorrelationoftheangiotensinsystemwithglaucomahas beenexplored,andpilotstudiesevaluatingthepotential utilityofangiotensin-converting-enzymeinhibitor(ACEI) andARBonthecontrolofocularpressurewereperformed inanimalmodels [24] .However,toourknowledge,research regardingtheeffectsofARBinthefibrosisoftheTenon's capsulehasnotbeenreported;thismayrepresentanew therapeutictargetforsafelyimprovingthesuccessrateof GFSinthefuture. MATERIALSANDMETHODS PrimarySubconjunctivaFibroblastCellCulture Human subconjunctivalfibroblastswereisolatedfrompatientswith theirinformedoralconsent(withoutstipend)andthe approvalofourinstitutionalethicscommittee.Thetenetsof theDeclarationofHelsinkiwerefollowed.Tissuebiopsies werecutintopieces,0.5-1mm,thentreatedaspreviously described [25] .Primarycellculturesfromthesetissueswere maintainedinculturemedium [DMEMwith10%(vol/vol) fetalbovineserum(FBS),penicillin(100units/mL), streptomycin(100units/mL;SigmaAldrich)].Thecells werepassagedwhentheyachieved80%confluence,and thecellsfromthe3 rd tothe7 th passagewereusedfor experiments.
Methyl Thiazol Tetrazolium Cytotoxicity Assay of CulturedCells Fivethousandfibroblastsperwellwere seededinto96-wellplates.Aftertheadhesionofcellstothe bottomofplatesafter12h,agradientofconcentrationof olmesartan [dissolvedinphosphatebuffersolution(PBS)] wasaddedto completeculturemediumatafinal concentrationsof2滋 mol/mL,1.5 滋mol/mL,1.25 滋mol/mL, 1 滋mol/mL,0.75 滋mol/mL,0.5 滋mol/mL,or0滋 mol/mL (control)andincubatedfor48h.Thecolorimetrictestwith tetrazoliumsaltmethylthiazoltetrazolium [MTT,3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide]was performed [26] .Afterdissolvingthepurplereactionproductin DMSO,theopticaldensityofeachwellwasmeasuredusing anautomaticplatereaderat490nmwavelength(Bio-tek, USA).Therateofcellinhibitionwascalculatedusingthe followingequationto establishthe concentrationof olmesartantouseforfurtherexperiments. Inhibitionrate=(OD C -OD O )/OD C 伊100%(OD C :ODofthe blankcontrol;OD O :ODofolmesartantreated) [27] . outoftheprimarytenon'stissueunder100 伊 magnification;D,E,F:Fibroblaststreatedwithincreasedconcentrationofolmesartan (0.75 滋mol/mL,1.5 滋mol/mL,2滋 mol/mL)inMTTwith100伊 magnification;G,H,I:Fibroblastsincontrol,1.25 滋mol/mL,1.5 滋mol/mL olmesartantreatedfibroblastsinMTTwith200伊 magnification.
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Figure3PCRofmRNAexpression
A:MMP-2mRNA; B:TIMP-2mRNA;C:TIMP-1mRNA;D:PCNAmRNA. [29] .MMP-2hasapivotalroleintheMMP familythroughmutualregulationwiththeothermembersin thefamily [30] .InTenon'sfibroblasts,MMP-2maybe involved,asapro-proliferationfactor,inthemolecular signalingtoenhancecellproliferationactivity.Thisisin accordancewiththestudyofYang 's [31] ,whichshowed ahigherMMP-2expressioninthefibroblastsofthemore activestageofthepterygium.Moreover,targetinginMMP-2 inhibitioncaninducetumorcellapoptosisandreducescar formation [32] [33] .NomatterolmesartansuppressedMMP-2 expressionthroughfibroblastsinhibitionortheeffectson cross-talkingofcellmoleculesitparticipatescanrestrain fibroblastproliferation,fibroblastproliferationandMMP-2 expressionalteredinparallel.Simultaneously,withthe increasedexpressionofTIMP-1 andTIMP-2,the endogenousinhibitorsofMMPs,furthersuppressedthe activityofMMPs.
,olmesartansuppressedtheinflammatoryreactionin therabbiteyesurgicalmodel.Thenumberofinflammatory cells decreasedwiththesubconjunctivalinjectionof olmesartan.Thesecellsincludefibroblastsmacrophagesand neutrophils.Excessivelyfibroblastproliferationandactivated macrophagemigrationcaninteractwithmultiple inflammatoryfactors,whichstrengthenstheinflammatory effectsandinducesfibrosis [34] . [35] [36] [37] . Becauseendothelialcellsofbloodvesselsadapttoboth physiologicalandpathological(inflammationand tumorigenesis) environmentscontinuously,tissuerepair processesbeginwiththeinjury-activatedacuteinflammation reaction,duringthis process,cytokinesrelatedto angiogenesisarereleasedfromthevesselsadjacenttothe injuryarea,whichinducesvascularsproutingandthe productionofgranulationtissuethatishighlyvascularized. Withoutappropriatebalancemechanisms,newlyformed bloodvesselsdonotregress.Onthecontrary,apositive feedbackloopisformedtoenhancefurtherinflammatory responses.WiththeparticipationofMMP-2,membrane-type matrixmetalloproteinase(MT1-MMP),theECM was degraded,enablingnewvascularsproutstospreadand progress.AfterGFS,similarprocessesoccurred,asmediated byVEGF,inducingscarformation [38] [39] .Therefore,olmesartan dampenedthiscourse theinhibitionofMMP-2and correspondinglydecreasesangiogenesis. Anotherproliferativerelatedfactor-PCNAwasalso examinedduringthestudy.Itsexpressionwassuppressedby olmesartanboth and .PCNA,aprotein presentineukaryoticcells,actsasaDNAclamp,encircles DNA,andpromotesDNAsynthesisandrepair;meanwhile, PCNAcanbindtoCDK/cyclinandmodulatetheCDK2and substratereaction,withanegativeeffectoncellapoptosis. 
